Streetbeat News

Regulatory

BVN

RGLD

VALE

President Biden plans to impose a 25% tariff on certain Chinese steel and aluminum imports to boost the U.S. steel sector and protect American manufacturing jobs. Royal Gold Inc (RGLD) issued its 2024 guidance, expecting sales volumes in gold, silver, copper, and other metals with projected DD&A expenses and an effective tax rate. Vale (VALE) reported a 15% increase in iron ore sales and a 6% production increase, with notable rises in pellet and copper output but a decrease in nickel production. Compania de Minas Buenaventura (BVN) announced first-quarter results, meeting or exceeding several production targets across its operations.

Portfolio Pulse from austin@walkonholdings.com

April 17, 2024 | 9:31 pm

JEWL

Adamas One Corp. has received an extension from NASDAQ until May 20th, 2024, to file its overdue financial statements, allowing it more time to regain compliance with NASDAQ's listing rule.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 9:29 pm

MRMD

At the Benzinga Cannabis Capital Conference in Florida, MariMed's CCO Howard Schacter discussed the challenges of maintaining brand consistency across states due to varying regulations, emphasizing the importance of quality and a unified brand strategy. Kristi Palmer of Kiva Confections and Angela Pih of CCELL also highlighted the significance of product consistency, the role of budtenders in customer retention, and the complexities of scaling in the cannabis industry.

Portfolio Pulse from Rolando García

April 17, 2024 | 9:23 pm

NKTR

Nektar Therapeutics has regained compliance with Nasdaq's Minimum Bid Price Requirement for continued listing, as its stock maintained a closing bid price of $1.00 or greater for 10 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 9:16 pm

JEWL

Adamas One Corp has received a notification from Nasdaq regarding non-compliance with Listing Rule 5550(a)(2), which could impact its stock listing status.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 9:11 pm

TSLA

U.S. Secretary of Transportation Pete Buttigieg emphasized the importance of EV adoption in the U.S., comparing skeptics to those who doubted the transition from landlines to cell phones. Despite recent job cuts at Tesla, Buttigieg highlighted the increasing competition in the EV market, including from Chinese companies, and reiterated the growth in EV sales each year in the U.S. He stressed the need for the U.S. to not fall behind China in EV production and mentioned government support for EV affordability through tax credits. EV sales in the U.S. reached 1.2 million units in 2023, a 46.3% increase from the previous year, with Tesla leading the market.

Portfolio Pulse from Chris Katje

April 17, 2024 | 8:28 pm

BNO

USO

Venezuela's Oil Minister has stated that US sanctions will not have an impact on the country's oil industry, according to Bloomberg. This statement comes amid ongoing tensions between Venezuela and the United States, with the US imposing sanctions as a means to pressure Venezuela on various fronts, including its oil exports.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:16 pm

EOLS

Evolus, Inc. (NASDAQ:EOLS) announced the publication of Phase 2 study results in the Aesthetic Surgery Journal, demonstrating the safety and 6-month duration of effect of its 'extra-strength' 40U Jeuveau formulation for treating moderate to severe glabellar lines. The study, which compared Jeuveau 40U against two active controls (BOTOX 20U and Jeuveau 20U), showed a similar safety profile across all groups, with the majority of adverse events being mild and no serious adverse events reported. This data was presented at the 2023 ASDS Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:13 pm

RLYB

Rallybio Corporation (NASDAQ:RLYB) presented results from a FNAIT systematic literature review and meta-analysis at the AMCP 2024 Annual Meeting, showing a 2.2% HPA-1a negative frequency among nearly 200,000 screened pregnant women. Approximately 33% of these women are at a higher risk for alloimmunization. Rallybio is developing RLYB212, a novel therapy aimed at preventing alloimmunization in pregnant women to mitigate FNAIT risks. The company plans to initiate a Phase 2 dose confirmation study for RLYB212 in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 8:08 pm

MSOS

Adam Wilks comments on the potential for growth in the cannabis industry with federal legalization, indicating that the industry is just beginning to tap into its potential. The Cannabis Capital Conference offers live access for subscribers and new users to discuss such topics.

Portfolio Pulse from Benzinga Newsdesk

April 17, 2024 | 7:59 pm